Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer
- 2 September 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 57 (5), 647-653
- https://doi.org/10.1007/s00280-005-0095-3
Abstract
Purpose: This phase II study was conducted to evaluate the efficacy and toxicity of single-agent gemcitabine in patients with advanced or metastatic biliary tract cancer. Patients and methods: Gemcitabine 1,000 mg/m2 was administered as an intravenous 30-min infusion on days 1, 8, and 15 for every 28 days. Results: Forty chemonaive patients with a median age of 61 (range 33–73) were enrolled, and all 40 patients were involved in efficacy and safety analyses. Seven (17.5%) achieved partial response; 15 (37.5%) had stable disease; 17 (42.5%) had progressive disease; and 1 (2.5%) was not evaluated. The median survival time was 7.6 months, and the 1-year survival rate was 25.0%. Grade 3/4 neutropenia occurred in 12 patients (30.0%), leukopenia in five patients (12.5%), and anemia in four patients (10.0%). The most common grade 3/4 nonhematologic toxicities were elevated ALT (15.0%) and elevated γ-GTP (12.5%). One patient had grade 4 hemolytic uremic syndrome and recovered after discontinuation of gemcitabine. Conclusions: In single-agent therapy, gemcitabine demonstrated moderate efficacy with manageable toxicity in patients with advanced or metastatic biliary tract cancer. Further evaluations are warranted, including the exact impact of gemcitabine on the management of advanced or metastatic biliary tract cancer.Keywords
This publication has 26 references indexed in Scilit:
- A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced Biliary Tree CarcinomaAmerican Journal of Clinical Oncology, 2004
- Gemcitabine‐associated thrombotic microangiopathyCancer, 2004
- Chemotherapy for biliary tract cancer in JapanSeminars in Oncology, 2002
- A review of hemolytic uremic syndrome in patients treated with gemcitabine therapyCancer, 1999
- Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas.Journal of Clinical Oncology, 1996
- Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumoursEuropean Journal Of Cancer, 1995
- Epirubicin-Sequential Methotrexate-5-Fluorouracil-Leucovorin Treatment in Advanced Cancer of the Extrahepatic Biliary SystemAmerican Journal of Clinical Oncology, 1994
- 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.Journal of Clinical Oncology, 1984
- Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancerCancer, 1984
- Adenocarcinomas of stomach, pancreas, liver, and biliary tracts.Survival of 328 patients treated with fluoropyrimidine therapyCancer, 1974